» Articles » PMID: 25882551

Liposome-bound TRAIL Induces Superior DR5 Clustering and Enhanced DISC Recruitment in Histiocytic Lymphoma U937 Cells

Overview
Journal Leuk Res
Date 2015 Apr 18
PMID 25882551
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Human Apo2-Ligand/TRAIL is a promising antitumor agent. Our group demonstrated that TRAIL was physiologically released to the extracellular medium inserted in lipid vesicles, known as exosomes. Recently we demonstrated that artificial lipid nanoparticles coated with bioactive TRAIL (LUV-TRAIL), which resemble the natural exosomes, greatly improved TRAIL activity compared with the soluble form of this death ligand and were able to induce apoptosis in hematological malignancies. In this study we have deepened the underlying mechanism of action of LUV-TRAIL in hematologic cells. Using histiocytic lymphoma U937 cells, we demonstrated that TRAIL signaling almost exclusively depends on DR5 despite these cells expressing high amounts of DR4, and proved that LUV-TRAIL's higher pro-apoptotic effect relies on its superior ability to induce DR5 clustering on cell surface, therefore enhancing DISC recruitment and triggering caspase activation more efficiently than the soluble form of TRAIL.

Citing Articles

Ionizable Lipid Nanoparticle-Mediated TRAIL mRNA Delivery in the Tumor Microenvironment to Inhibit Colon Cancer Progression.

da Silva W, Costa P, Ricardo Aluotto Scalzo Junior S, Ferreira H, Dias Moura Prazeres P, Campos C Int J Nanomedicine. 2024; 19:2655-2673.

PMID: 38500680 PMC: 10946446. DOI: 10.2147/IJN.S452896.


Tuning of TRAIL clustering on the surface of nanoscale liposomes by phase separation.

Zhang Z, King M Nanoscale Adv. 2024; 6(2):402-405.

PMID: 38235079 PMC: 10790813. DOI: 10.1039/d3na00841j.


Nano-TRAIL: a promising path to cancer therapy.

Gampa S, Garimella S, Pandrangi S Cancer Drug Resist. 2023; 6(1):78-102.

PMID: 37065863 PMC: 10099604. DOI: 10.20517/cdr.2022.82.


Recent Advances in the Development of Nanodelivery Systems Targeting the TRAIL Death Receptor Pathway.

Yagolovich A, Gasparian M, Dolgikh D Pharmaceutics. 2023; 15(2).

PMID: 36839837 PMC: 9961178. DOI: 10.3390/pharmaceutics15020515.


DR5 Up-Regulation Induced by Dichloroacetate Sensitizes Tumor Cells to Lipid Nanoparticles Decorated with TRAIL.

Marco-Brualla J, de Miguel D, Martinez-Lostao L, Anel A J Clin Med. 2023; 12(2).

PMID: 36675536 PMC: 9864242. DOI: 10.3390/jcm12020608.